NCT05680298View on ClinicalTrials.gov

Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

December 22, 2023

Study Completion Date

March 15, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

solution for injection, Subcutaneous injection

Trial Locations (1)

Unknown

Beijing Children's hospital, Beijing

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05680298 - Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China | Biotech Hunter | Biotech Hunter